Idelalisib in relapsed/refractory diffuse large B‐cell lymphoma: results from a Nordic Lymphoma Group phase II trial

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation

(2020) Annalen Bleckmann et al.   ANNALS OF HEMATOLOGY

Rapid and complete response to idelalisib in a case of Richter syndrome

(2019) Cristina Bagacean et al.   OncoTargets and Therapy

The Role of PI3K Inhibition in Lymphoid Malignancies

(2019) Gottfried von Keudell et al.   Current Hematologic Malignancy Reports

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

(2018) Andrea Visentin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

(2018) Bjoern Chapuy et al.   NATURE MEDICINE

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

(2018) Roland Schmitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

(2015) Wyndham H Wilson et al.   NATURE MEDICINE

The Genetic Landscape of Diffuse Large B-Cell Lymphoma

(2015) Laura Pasqualucci et al.   SEMINARS IN HEMATOLOGY

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

(2013) M. Pfeifer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA